The pharmacokinetics and in dosing regimens of the currently available pegylated interferon (peginterferon) alfa molecules differ greatly, depending on the size and nature of their polyethylene glycol (PEG) moiety. Peginterferon alfa-2a has a branched 40 kDa PEG chain covalently attached to lysine residues and circulates as an intact molecule. On the other hand, peginterferon alfa-2b has a linear 12 kDa PEG chain covalently attached to interferon-a-2b via an unstable urethane bond that is hydrolysed after injection, releasing native interferon alfa-2b. The difference in pegylation between the two peginterferons has a significant impact on their pharmacokinetic properties. Data from comparative and non-comparative studies indicate that peginterferon alfa-2b has a shorter half-life in serum than peginterferon alfa-2a, and a significant proportion of patients receiving peginterferon alfa-2b may have trough concentrations below the limit of detection during the latter part of the 7-day dosing schedule. However, the pharmacodynamic parameters of the two drugs appear to be similar.

Bruno, R., Sacchi, P., Cima, S., Maiocchi, L., Novati, S., Filice, G., et al. (2012). Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. JOURNAL OF VIRAL HEPATITIS, 19(s1), 33-36 [10.1111/j.1365-2893.2011.01519.x].

Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles

Fagiuoli S
2012

Abstract

The pharmacokinetics and in dosing regimens of the currently available pegylated interferon (peginterferon) alfa molecules differ greatly, depending on the size and nature of their polyethylene glycol (PEG) moiety. Peginterferon alfa-2a has a branched 40 kDa PEG chain covalently attached to lysine residues and circulates as an intact molecule. On the other hand, peginterferon alfa-2b has a linear 12 kDa PEG chain covalently attached to interferon-a-2b via an unstable urethane bond that is hydrolysed after injection, releasing native interferon alfa-2b. The difference in pegylation between the two peginterferons has a significant impact on their pharmacokinetic properties. Data from comparative and non-comparative studies indicate that peginterferon alfa-2b has a shorter half-life in serum than peginterferon alfa-2a, and a significant proportion of patients receiving peginterferon alfa-2b may have trough concentrations below the limit of detection during the latter part of the 7-day dosing schedule. However, the pharmacodynamic parameters of the two drugs appear to be similar.
Articolo in rivista - Articolo scientifico
HCV; peginterferon; pharmacodynamic; pharmacokinetic;
English
33
36
4
Bruno, R., Sacchi, P., Cima, S., Maiocchi, L., Novati, S., Filice, G., et al. (2012). Comparison of peginterferon pharmacokinetic and pharmacodynamic profiles. JOURNAL OF VIRAL HEPATITIS, 19(s1), 33-36 [10.1111/j.1365-2893.2011.01519.x].
Bruno, R; Sacchi, P; Cima, S; Maiocchi, L; Novati, S; Filice, G; Fagiuoli, S
File in questo prodotto:
File Dimensione Formato  
J.Viral Hep. Bruno.pdf

Solo gestori archivio

Dimensione 102.61 kB
Formato Adobe PDF
102.61 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/353454
Citazioni
  • Scopus 8
  • ???jsp.display-item.citation.isi??? 11
Social impact